



Selzentry® (maraviroc) – Expanded indication

- On October 30, 2020, the [FDA approved](#) ViiV Healthcare's [Selzentry \(maraviroc\)](#), in combination with other antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 2 kg.
 - Selzentry was previously approved for this indication in patients 2 years of age and older weighing at least 10 kg.
 - Selzentry is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
- Selzentry carries a boxed warning for hepatotoxicity.
- The recommended dosage of Selzentry in pediatric patients should be based on body weight (kg) and should not exceed the recommended adult dose. The recommended dosage also differs based on concomitant medications due to drug interactions. Selzentry tablets and oral solution are taken twice daily by mouth and may be taken with or without food.
 - Prior to initiation of Selzentry for treatment of HIV-1 infection, test all patients for CCR5 tropism using a highly sensitive tropism assay.
 - Selzentry must be given in combination with other antiretroviral medications.
 - Refer to the Selzentry drug label for adult dosing, complete pediatric dosing and other administration recommendations.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.